Acute Myeloid Leukemia Therapeutics Market Report by Treatment Type, Drug Type, Route of Administration, and Region 2024-2032
급성 골수성 백혈병 치료제 세계 시장 규모는 2023년 12억 950만 달러에 달했습니다. 향후 IMARC Group은 2032년까지 시장 규모가 32억 360만 달러에 달해 2024년부터 2032년까지 11.1%의 연평균 성장률(CAGR)을 기록할 것으로 예상했습니다.
급성 골수성 백혈병(AML)은 비정상적인 세포가 빠르게 증식하는 클론성 악성 종양입니다. 주로 골수와 백혈구(WBC)에 영향을 미치며 피부 변색, 호흡곤란, 피로, 고열, 체중 감소, 잇몸 출혈, 코피가 특징입니다. 일반적으로 사용되는 AML 치료법에는 화학요법, 면역요법, 분자 표적 요법, 호르몬 요법, 수술 등이 있습니다. 이러한 치료법은 일반적으로 효과를 높이고 합병증을 최소화하며 신체의 면역 체계를 강화하기 위해 줄기세포 이식과 함께 사용됩니다.
전 세계적으로 백혈병의 유병률이 증가하고 있는 것은 시장 성장을 촉진하는 중요한 요인 중 하나입니다. 또한, 백혈병은 주로 체내 유전자 돌연변이에 의해 발생하며, 혈액 세포 생산 수준에 영향을 미치는 AML은 이러한 질병에 취약한 노인 인구의 증가로 인해 시장 성장을 촉진하고 있습니다. 이에 따라 병용요법 및 표적치료제가 널리 채택되고 암 치료에 사용할 수 있는 대체 요법에 대한 인식이 높아지면서 시장 성장에 긍정적인 영향을 미치고 있습니다. 또한, 개선된 면역독소, 알킬화제, 단클론항체, 다제내성 조절제의 등장도 시장 성장을 촉진하는 주요 요인으로 작용하고 있습니다. 이러한 치료제는 치료 효과의 연장, 더 높은 효능, 백혈병 세포의 조기 및 정확한 식별, 암 재발의 가능성 감소를 가져옵니다. 종양학 분야의 광범위한 연구개발(R&D) 활동과 기존 의료 인프라의 대폭적인 개선과 같은 다른 요인들도 시장을 더욱 견인할 것으로 예상됩니다.
본 보고서에서 다루는 주요 질문
- 세계 급성 골수성 백혈병 치료제 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 변화할 것인가?
- COVID-19는 세계 급성 골수성 백혈병 치료제 시장에 어떤 영향을 미쳤을까?
- 주요 지역 시장이란?
- 치료 유형별 시장 현황은?
- 약제 종류별 시장 현황은?
- 투여 경로에 따른 시장 분석은?
- 산업 가치사슬의 다양한 단계는 무엇인가?
- 업계의 주요 촉진요인과 과제는 무엇인가?
- 세계 급성 골수성 백혈병 치료제 시장의 구조와 주요 플레이어는?
- 업계의 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 급성 골수성 백혈병 치료제 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 치료 유형별
- 시타라빈
- 안트라사이클린계 약제
- 알킬화제
- 대사 저해 물질
- 티로신 키나아제 억제제
- 기타
제7장 시장 내역 : 약물 유형별
제8장 시장 내역 : 투여 경로별
제9장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 구매자의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 참여업체의 위협
- 대체품의 위협
제13장 가격 분석
제14장 경쟁 상황
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Abbvie Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company
- Celgene
- Roche Holding AG
- Gilead Sciences Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
ksm
The global acute myeloid leukemia therapeutics market size reached US$ 1,209.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 3,203.6 Million by 2032, exhibiting a growth rate (CAGR) of 11.1% during 2024-2032.
Acute myeloid leukemia (AML) refers to a clonal malignancy leading to the rapid growth of abnormal cells. It primarily impacts the bone marrow and white blood cells (WBCs) and is characterized by the discoloration of skin, breathlessness, fatigue, high body temperatures, weight loss, bleeding gums and nosebleeds. Some of the commonly used AML therapies include chemo-, immuno-, targeted- and hormonal therapies and surgical procedures. These therapeutics are usually combined with stem cell transplants to increase the efficacy, minimize complications and strengthen the immune system of the body.
The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such disorders, is also driving the market growth. AML is primarily caused by genetic mutations in the body that impacts the levels of blood cell production. In line with this, the widespread adoption of combination and targeted therapies and increasing awareness regarding the available alternatives for cancer treatment are also favoring the market growth. Additionally, the advent of improved immunotoxins, alkylating agents, monoclonal antibodies and multidrug-resistant modulators is another major growth-inducing factor. These therapeutics offer prolonged results, higher efficacy, early and accurate identification of leukemia cells and reduced chances of cancer relapse. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with significant improvements in the existing healthcare infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global acute myeloid leukemia therapeutics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on treatment type, drug type and route of administration.
Breakup by Treatment Type:
Cytarabine
Anthracycline Drugs
Alkylating Agents
Anti-Metabolites
Tyrosine Kinase Inhibitors
Others
Breakup by Drug Type:
Small Molecule Drugs
Biopharmaceuticals
Breakup by Route of Administration:
Oral
Injectables
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene, Roche Holding AG, Gilead Sciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.
Key Questions Answered in This Report:
- How has the global acute myeloid leukemia therapeutics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global acute myeloid leukemia therapeutics market?
- What are the key regional markets?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the route of administration?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global acute myeloid leukemia therapeutics market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Acute Myeloid Leukemia Therapeutics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Treatment Type
- 6.1 Cytarabine
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Anthracycline Drugs
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Alkylating Agents
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Anti-Metabolites
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Tyrosine Kinase Inhibitors
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
7 Market Breakup by Drug Type
- 7.1 Small Molecule Drugs
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Biopharmaceuticals
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Route of Administration
- 8.1 Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Injectables
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbvie Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Amgen Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Bristol-Myers Squibb Company
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Celgene
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 SWOT Analysis
- 14.3.5 Roche Holding AG
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.6 Gilead Sciences Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Novartis AG
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Pfizer Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Sanofi S.A.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.10 Takeda Pharmaceutical Company Limited
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
